We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Eli Lilly and Co | NYSE:LLY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.89 | -0.11% | 776.88 | 781.3499 | 772.20 | 779.00 | 1,054,794 | 18:19:51 |
From May 2019 to May 2024
By Michael Dabaie
Eli Lilly & Co. said new 36-week data showed higher investigational doses of Trulicity were well-tolerated and led to A1C reductions up to 1.9% and weight reductions up to 10.4 pounds in people with type 2 diabetes.
The results from Lilly's Award-11 trial, which evaluated higher investigational doses of Trulicity, 3 mg and 4.5 mg, compared to Trulicity 1.5 mg, were published in the Journal of the Endocrine Society.
The trial "confirmed our expectations that a higher investigational dose of Trulicity would lead to superior blood glucose and weight reductions in people with type 2 diabetes compared to Trulicity 1.5 mg," said Juan Pablo Frias, medical director and principal investigator at National Research Institute.
Results at 52 weeks were consistent with the 36-week results and further details will be disclosed at a later date, Lilly said. The Award-11 results have been submitted to regulatory authorities in the U.S. and Europe for review.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
May 08, 2020 15:30 ET (19:30 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Eli Lilly Chart |
1 Month Eli Lilly Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
